01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; diagnostic reagents for
scientific or research use; chemicals for use in performing
nucleic acid polymerase chain reactions [other than medical
and veterinary]; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology research;
reagents in kit form for conducting enzyme-linked
immunosorbent assays (elisa) [other than for medical or
veterinary purposes]; nucleic acid amplification reagents
[other than for medical use]. In vitro diagnostic preparations for medical use; diagnostic
reagents for medical use; reagents for in-vitro laboratory
use [for medical purposes]; chemical preparations for use in
DNA analysis [medical]; nucleic acid sequences for medical
and veterinary purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; electric instruments for use
in the diagnosis of blood [laboratory apparatus];
quantitative polymerase chain reaction [PCR] instruments for
scientific use; real-time polymerase chain reaction [PCR]
instruments for scientific use; diagnostic apparatus for
research laboratory use; DNA microarray; devices for
analyzing protein sequence used as laboratory apparatus;
research laboratory analyzers for measuring, testing and
analyzing blood and other bodily fluids; computer software
for use in medical decision support systems; workflow
management system software; bioinformatics software. Testing apparatus for medical purposes; diagnostic apparatus
for medical purposes used in medical laboratories; real-time
polymerase chain reaction [PCR] instruments for medical use;
diagnostic testing instruments for use in immunoassay
procedure [medical]; immunochemical medical diagnostic
testing apparatus for detecting and measuring antibody
levels; apparatus for DNA and RNA testing for medical
purposes; analysing apparatus for medical purposes.
Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present disclosure relates to systems and methods for processing signals from wearable motion sensors associated with gait activity of a subject. In some cases, a signal representative of the gait activity of the subject may be received from the wearable motion sensors. One or more directional components of the signal, which are independent of an orientation of the wearable motion sensors on the subject, may be identified. One or more gait features may be extracted from the signal based on the one or more directional components of the signal. At least one of a diagnosis, a progression, a treatment, and a treatment response for a neurological dysfunction may be determined based on the one or more gait features.
The Walter and Eliza Hall Institute of Medical Research (Australia)
Inventor
Bruncko, Milan
Ding, Hong
Doherty, George A.
Elmore, Steven W.
Hasvold, Lisa A.
Hexamer, Laura
Kunzer, Aaron R.
Song, Xiaohong
Souers, Andrew J.
Sullivan, Gerard M.
Tao, Zhi-Fu
Wang, Gary T.
Wang, Le
Wang, Xilu
Wendt, Michael D.
Mantei, Robert
Hansen, Todd M.
Abstract
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
5.
COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
The present invention relates to methods for treating multiple sclerosis (MS) in a patient which in some cases involves subcutaneously administering an anti-CD20 antibody into the patient at a dose of about 920 mg. Compositions, formulations and articles of manufacture with instructions for such use are also included.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 47/42 - Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
6.
BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE
The present invention relates to compounds of formula (Ia), wherein R2, T1to T4, and M1to M3 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
7.
MATERIALS AND METHODS FOR DETERMINING GAIN OR LOSS OF MRNA TRANSCRIPTS
Methods of evaluating mRNA or cDNA are provided. Instead of evaluating the mRNA or cDNA as a whole, multiple distinct portions of the mRNA or cDNA (such as different exons or untranslated regions) are separately quantified. The separate quantities are then evaluated by a trained classifier, which converts the separate quantities to a composite score indicative of the expression level of the mRNA or corresponding cDNA.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
The invention provides compounds having the general formula (I) wherein X, Y, Z, U, V, and R1to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the5 compounds in the treatment or prevention of diseases that are associated with SARM1.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61P 25/00 - Drugs for disorders of the nervous system
9.
MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE
The present invention relates to compounds of formula (I-2), wherein R1to R3, Q1, Q2, A1to A7and M1 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
11.
RATIOS OF sFlt-1 TO P1GF OR ENDOGLIN TO P1GF AS BIOMARKERS FOR PREECLAMPSIA RELATED ADVERSE OUTCOMES AFTER BIRTH
The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.
A method for controlling a laboratory system or device comprising at least one pipettor with a pressure sensor, at least one humidity sensor, at least one temperature sensor, and a control unit. The control unit receiving a humidity value from the humidity sensor and a temperature value from the temperature sensor, comparing the pair of humidity and temperature values with a threshold database connected to the control unit, the threshold database comprising, for different pairs of humidity and temperature values, instructions to activate or deactivate an anti droplet control system of the pipettor, determining if the anti droplet system of the pipettor has to be activated or deactivated, activating or deactivating said anti droplet system of the pipettor.
Disclosed herein are techniques for facilitating a clinical decision for a patient based on identifying a group of patients having similar attributes as the patient. The group of patients can be identified using information from a predictive machine learning model that performs a clinical prediction for the patient. At least some of the attributes of the group of patients can be output to support a clinical decision. The attributes may include, for example, biography data of the patient, results of one or more laboratory tests of the patient, biopsy image data of the patient, molecular biomarkers of the patient, a tumor site of the patient, and a tumor stage of the patient.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
14.
METHODS AND SYSTEMS FOR MEAL EVENT DETECTION AND MEDICATION BOLUS CALCULATION
A method for medication bolus calculation has been developed. The method includes receiving physiological measurements from an analyte sensor coupled to a user, receiving data corresponding to at least one meal event including a timestamp corresponding to when a meal was consumed, identifying a missed meal event time corresponding to a meal consumed by the user but not to the timestamp of any meal event, the recommended bolus being calculated based, at least in part, upon an length of time elapsed from the missed meal event time to a current time, and generating an output message indicating the recommended bolus of the medication.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A method implemented by one or more computer device includes accessing a set of medical data associated with a patient, in which the set of medical data includes a plurality of modalities of medical data. The method includes inputting one or more one of the plurality of modalities of medical data into a first machine-learning model trained to generate a first vector representation and inputting another one of the plurality of modalities of medical data into a second machine-learning model trained to generate a second vector representation. The method includes generating a combined vector representation based on the first vector representation and the second vector representation, and storing the combined vector representation to a database associated with the one or more computing devices.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
17.
COMPUTER IMPLEMENTED METHOD FOR DESIGNING A COMPLEX PART OF AN IN-VITRO DIAGNOSTIC INSTRUMENT
A computer implemented method for designing a complex part of an in-vitro diagnostic instrument is disclosed. The method includes retrieving at least one target constraint, retrieving at least one set of input parameters, determining at least one design solution of the complex part by using at least one iterative algorithm considering the input parameters, comparing the candidate complex part to the target constraint, and rating the candidate complex part depending on the comparison.
A machine learning and/or deep learning framework forecasts epidemic or pandemic cases and deaths. Multiple open data sources relevant for the pandemic or epidemic evolution in a geographic area, such as the United States or another country or region, can be processed to extract a plurality of features, such as localized (i.e., county level, city level, regional level, province level, etc.) cases and deaths, demographics and socioeconomic factors, non-medical interventions, and mobility (i.e., from cell phone and/or GPS data). The learning can be used to predict future cases and deaths at localized levels and to recommend healthcare resources that may be needed.
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
A method for increasing operational security of a laboratory system or device comprising: a reagent storage area (1) comprising at least two reagent drawers (2, 3) mounted slidably along a first axis Y between an open position (O) and a closed position (C) and arranged stacked with respect to a second axis Z perpendicular to the first axis Y, and having each a position sensor (P2, P3) for determining the closed position (C) of the respective reagent drawer (2, 3), at least one robotic handler head (4) movably arranged in the reagent storage area at least along the first axis Y and the second axis Z a control unit (5) configured to control the operation of the robotic handler head (4) and connected to the position sensors (P2, P3), the method comprising the steps of defining for each reagent drawer (2, 3) a first forbidden zone along the first axis Y (Y) and a second forbidden along the second axis Z (Z2, Z3), determining by means of the position sensors (P2, P3) if the reagent storage drawers (2, 3) are in the closed position (C), and control the operation of the handler head (4).
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
20.
ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
A graphical user interface for displaying an electronic medical record associated with a patient is provided. The graphical user interface may include an area configured to display patient information, which may include at least a name of the patient. The graphical user interface may also include an indicator displayed in association with the name of the patient. The indicator may include information specifying that the patient is potentially eligible for one or more trials, the patient is participating in one or more trials, or the patient has completed one or more trials.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G06F 3/0482 - Interaction with lists of selectable items, e.g. menus
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
22.
NEW SOLID FORMS OF (3R)-N-[2-CYANO-4-FLUORO-3-(3-METHYL-4-OXO-QUINAZOLIN-6-YL)OXY-PHENYL]- 3-FLUORO-PYRROLIDINE-1-SULFONAMIDE
The present invention provides solid forms of (3R)-N-[2-cyano-4- fluoro-3-(3-methyl-4-oxo-quinazolin -6-yl )oxy - phenyl]-3-fluoro- pyrrolidine-1-sulfonamide of formula (I) and solvates thereof, as well as therapeutic uses thereof and pharmaceutical composition comprising them.
C07D 487/12 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains three hetero rings
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
23.
PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
The present invention relates to compounds of formula (I), wherein R1, R2, R3, Y, Q1, Q2, Q3, Q4 and Q5 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A method for controlling an anti droplet system of a laboratory system or device comprising at least one air displacement pipettor with a pressure sensor and a control unit for controlling operation of the pipettor, the method comprising the following steps controlling the pipettor to be moved such that the pipettor tip is immerged in a fluid to be aspirated, aspirate a predetermined volume of fluid, move the pipettor such that the pipettor tip is emerged from the fluid, continuously monitoring the pressure above the fluid column in the pipettor tip and generating pressure curve over time, and determining if a pressure increase above the fluid column has been detected.
A laboratory system or device, comprising a reagent storage area (1) comprising at least two reagent drawers (2, 3) mounted slidably between an open position (O) and a closed position (C), each of the reagent drawers comprising receptacles for a plurality of reagent cartridges (RC1, RC2), and at least two locking mechanisms (4, 5) for respectively locking/unlocking the at least two reagent drawers (2, 3) when in the closed position (C), at least one robotic handler (6) and a control unit (7), wherein the reagent storage area (1) is subdivided in a loading zone (LZ), a storage zone (SZ) and a pipetting zone (PZ), and the reagent storage area (1) further comprises a handling zone (HZ).
The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are antibodies such as human or humanized antibodies with a modified heavy chain variable (VH) domain such that the antibodies adopt a constrained conformation (e.g., an i-shaped format) upon engaging the antigen(s) the antibodies bind to, thereby confer agonistic activities. In some cases, the antibodies are full-length antibodies (e.g., IgG antibodies). In some cases, the antibodies are monovalent antibodies (e.g., Fabs). In some cases, the antibodies target receptors which require clustering for activation (e.g., TNFR superfamily receptors). In some cases, the antibodies target two antigens on a molecule that have two or more subunits (e.g., an IL-2 receptor). Also provided herein are methods of making and using such antibodies and libraries for discovering or screening such antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
29.
ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
A method of classifying a tissue sample by a classification system includes identifying, by the classification system, a plurality of tiles corresponding to whole-slide image data of the tissue sample; generating, by the classification system, a plurality of semantic masks corresponding to the plurality of tiles, each one of the plurality of semantic masks identifying a cell boundary and a cell type of each cell within a corresponding tile of the plurality of tiles; generating, by the classification system, a plurality of cellular features for each tile of the plurality of tiles based on a corresponding one of the plurality of semantic masks; and classifying, by the classification system, the tissue sample based on the plurality of cellular features for each one of the plurality of tiles.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes];
diagnostic biomarker reagents for medical purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; instruments for diagnosis [for
scientific use]; quantitative polymerase chain reaction
[PCR] instruments for scientific use; real-time polymerase
chain reaction [PCR] instruments for scientific use;
diagnostic apparatus for research laboratory use; research
laboratory analyzers for measuring, testing and analyzing
blood and other bodily fluids, laboratory instrument for the
detection of pathogens and toxins in a biological sample for
research use. Medical apparatus and instruments; testing apparatus for
medical purposes; diagnostic apparatus for medical purposes;
real-time polymerase chain reaction [PCR] instruments for
medical use; diagnostic testing instruments for use in
immunoassay procedure [medical]; immunochemical medical
diagnostic testing apparatus for detecting and measuring
antibody levels; apparatus for analyzing substances [for
medical use]; diagnostic apparatus for medical purposes used
in medical laboratories.
The invention relates to novel compounds having the general formula (I) wherein A, R1, R2 and n are as described herein, composition including the compounds and methods of using the compounds.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
The present invention features RNA polynucleotide constructs comprising sequences targeting Huntingtin mRNA, polynucleotide constructs comprising a sequence encoding for such RNA constructs, and primary microRNA scaffolds. Constructs comprising sequences targeting Huntingtin mRNA and/or encoding for sequences targeting Huntingtin mRNA can be used, for example, for inhibiting mutant HTT expression and/or treating Huntington disease.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes];
diagnostic biomarker reagents for medical purposes. Medical apparatus and instruments; testing apparatus for
medical purposes; diagnostic apparatus for medical purposes;
real-time polymerase chain reaction [PCR] instruments for
medical use; diagnostic testing instruments for use in
immunoassay procedure [medical]; immunochemical medical
diagnostic testing apparatus for detecting and measuring
antibody levels; apparatus for analysing substances [for
medical use]; diagnostic apparatus for medical purposes used
in medical laboratories.
Provided are mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, provided are polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. Also provided are methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention is directed to pharmaceutical combinations for treating hepatitis B virus (HBV) infection comprising administering at least two, preferably two or three, different HBV therapeutics. In particular, the present invention relates to pharmaceutical combinations comprising an RNAi oligonucleotide targeting HBV and an anti-PDL1 antisense oligonucleotide.
Herein is reported a composition comprising a pair of a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises in the order a first part of a stem nucleic acid sequence, a cleavage site, a first stem loop nucleic acid sequences which 5′- and 3′-parts form a duplex, a first part of a catalytic core sequence, a second stem loop nucleic acid sequences which 5′- and 3′-parts form a duplex, a second part of the catalytic core sequence, and a second part of the stem nucleic acid sequence, which is complementary to the first part of the stem nucleic acid sequence and, thus, form a duplex therewith, wherein the second nucleic acid is complementary to at least a part of the first or the second part of the stem nucleic acid sequence, wherein binding of the second nucleic acid to the first nucleic acid results in a conformational change of the first nucleic acid, which is at least one of the dissociation of the first part of the first stem sequence from the second part of the stem sequence and the hybridization of one of the parts with the second nucleic acid, or the dissociation of loop I and loop II resulting in an inactivation of the catalytic activity, or the association of loop I and loop II resulting in an activation of the catalytic activity.
The present invention describes a secondary tube tray for use in an automated processing system, the tray comprising a base module and a secondary tube insert. Furthermore, the present invention describes a secondary tube handling module of an automated processing system for automatically processing biological sample, and a method of handling secondary tubes for use in automatically processing biological sample in an automated processing system.
B65C 9/02 - Devices for moving articles, e.g. containers, past labelling station
G01N 35/04 - Automatic analysis not limited to methods or materials provided for in any single one of groups ; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations - Details of the conveyor system
Pharmaceutical asset tracking systems and methods for pharmaceutical asset tracking are disclosed. The system comprises a pharmaceutical asset tracker to transmit pharmaceutical asset information to a communications device. The pharmaceutical asset information comprises an identifier for a pharmaceutical asset associated with the pharmaceutical asset tracker in a defined area. The communications device is responsive to communications via a crowdsourcing protocol, and the pharmaceutical asset tracker transmits the pharmaceutical asset information to the communications device via the responsive crowdsourcing protocol. The system comprises a server configured to receive the pharmaceutical asset information and location information from the communications device. The server may determine, based on the location information, a location of the asset, and provide for display information regarding a group of pharmaceutical assets determined to be at a specified location. The group is identified based on pharmaceutical asset information for each of the assets in the group.
Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.
Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
43.
BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
44.
COMBINATION THERAPY WITH FAP-TARGETED LYMPHOTOXIN BETA RECEPTOR AGONISTS
The present invention relates to combination therapies employing tumor targeted anti- CD3 bispecific antibodies (T cell engager) and FAP-targeted LTBR antibodies, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
45.
MEDICAL SYSTEM AND A METHOD FOR MONITORING THE STORAGE CONDITIONS THEREOF
A medical system (110) and a method for monitoring the storage conditions of at least one medical system (110) are disclosed. The medical system (110) comprises: - at least one analyte sensor (112) for detecting at least one analyte in a bodily fluid, the analyte sensor (112) being configured for at least partial transcutaneous insertion into a body tissue (114) of a user (116); and - at least one disabling device (118) operably connected to the analyte sensor (112), the disabling device (118) comprising at least one monitoring element (120), the monitoring element (120) being configured for undergoing a change in at least one mechanical property when storage conditions of the analyte sensor (112) are outside a specification range, the mechanical property change being configured such that the transcutaneous insertion of the analyte sensor (112) into the body tissue (114) is irreversibly prevented.
A method may include determining, within a first positron emission tomography and computed tomography (PET-CT) scan depicting a plurality of regions of a body, a first region including a lesion. A first portion of the first PET-CT scan depicting the first region but not a second region of the plurality of regions may be extracted to generate a second PET-CT scan having one or more initial dimensions. The one or more initial dimensions of the second PET-CT scan may be adjusted to one or more target dimensions by at least adding, to the second PET-CT scan, one or more voxels, and determining a value of each of the one or more voxels added to the second PET-CT scan. A segmentation model may be trained based on a training dataset that includes the second PET-CT scan adjusted to the one or more target dimensions.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; diagnostic reagents for
scientific or research use; chemicals for use in performing
nucleic acid polymerase chain reactions [other than medical
and veterinary]; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology research;
reagents in kit form for conducting enzyme-linked
immunosorbent assays (elisa) [other than for medical or
veterinary purposes]; nucleic acid amplification reagents
[other than for medical use]. In vitro diagnostic preparations for medical use; diagnostic
reagents for medical use; reagents for in-vitro laboratory
use [for medical purposes]; chemical preparations for use in
DNA analysis [medical]; nucleic acid sequences for medical
and veterinary purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; electric instruments for use
in the diagnosis of blood [laboratory apparatus];
quantitative polymerase chain reaction [PCR] instruments for
scientific use; real-time polymerase chain reaction [PCR]
instruments for scientific use; diagnostic apparatus for
research laboratory use; DNA microarray; devices for
analyzing protein sequence used as laboratory apparatus;
research laboratory analyzers for measuring, testing and
analyzing blood and other bodily fluids; computer software
for use in medical decision support systems; workflow
management system software; bioinformatics software. Testing apparatus for medical purposes; diagnostic apparatus
for medical purposes used in medical laboratories; real-time
polymerase chain reaction [PCR] instruments for medical use;
diagnostic testing instruments for use in immunoassay
procedure [medical]; immunochemical medical diagnostic
testing apparatus for detecting and measuring antibody
levels; apparatus for DNA and RNA testing for medical
purposes; analysing apparatus for medical purposes.
49.
METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY
The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention generally relates to humanized antigen binding receptors capable of specific binding to an Fc domain comprising the amino acid mutation P329G according to EU numbering. The present invention also relates to T cells, transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
51.
DETECTION OF AIR BUBBLES IN OPTICAL DETECTION UNIT
An in-vitro diagnostic (IVD) analyzer 200 comprising an optical detection unit 217 comprising a cuvette 214 for the optical measurement of a biological sample 2, 2′ is herein disclosed. The IVD analyzer 200 further comprises a piezo actuator 218 arranged on one side of the cuvette 214 configured to transmit ultrasonic waves 254, 254′ through the cuvette 214, a piezo receiver 218′ arranged on the opposite side of the cuvette 214 configured to receive ultrasonic waves 255, 255′, 255″ transmitted through the cuvette 214 and a controller 250 configured to operate according to either a lysis operating mode (L) or an air-detection operating mode (AD). According to the lysis operating mode (L) the piezo actuator 218 is configured to transmit ultrasonic waves 254′ through the cuvette 214 for disrupting cellular particles contained in the biological sample 2. According to the air-detection operating mode (AD) the piezo actuator 218 is configured to transmit ultrasonic waves 254 through the cuvette 214 and the controller 250 is configured to correlate changes in amplitude and/or shifts of phase of the ultrasonic waves 255, 255′, 255″ received by the piezo receiver 218′ relative to reference values with an eventual presence and quantity of air 3 in the cuvette 214, in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air 3. A respective automated method of operating the in-vitro diagnostic analyzer 200 in order to determine if the optical measurement of the biological sample 2, 2′ is affected by the presence of air is herein also disclosed.
This application relates to random polymer libraries and specific polymers that can be used, for example, in stabilizing high concentration protein compositions, such as high concentration antibody compositions.
The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle where the viscocity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention relates to systems and methods for analyzing data from motion activity monitoring technology. It is particularly, but not exclusively, concerned with a method for determining motion activity patterns during sleep.
The invention provides compounds having the general formula (I) wherein A1, A2, X1, X2, R1, R2, R3, R4, and R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
56.
PROCESS FOR THE PREPARATION OF A CHIRAL PYRROLO TRIAZOLE ALCOHOL
The invention relates to a novel process for the preparation of chiral pyrrolo triazole alcohols of the formula (I) wherein X is a halogen atom, n is an integer of 1, 2 or 3 and wherein the spiral bond (II) stands for (III) or for (IV) or mixtures of the enantiomers. The chiral pyrrolo triazole alcohols of the formula (I) are versatile intermediates for the preparation of compounds that have the potential to serve as active pharmaceutical ingredients in drugs.
The present invention relates to the treatment of liver cancer, e.g., hepatocellular carcinoma (HCC), e.g., resectable HCC. More specifically, the invention pertains to the treatment of patients having an HCC by administering (i) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab); (ii) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab), a VEGF antagonist (e.g., bevacizumab), and an anti-TIGIT antagonist antibody (e.g., tiragolumab); or (iii) a combination of a bispecific antibody that binds to PD-1 and LAGS (e.g., tobemstomig) and a VEGF antagonist (e.g., bevacizumab).
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
in situin situ. Advantageously, the method can be effectively used to detect barcode sequences in formalin-fixed paraffin-embedded (FFPE) tissue samples.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Provided herein are antibodies such as human or humanized antibodies with a modified heavy chain variable (VH) domain such that the antibodies adopt a constrained conformation (e.g., an i-shaped format) upon engaging the antigen(s) the antibodies bind to, thereby confer agonistic activities. In some cases, the antibodies are full-length antibodies (e.g., IgG antibodies). In some cases, the antibodies are monovalent antibodies (e.g., Fabs). In some cases, the antibodies target receptors which require clustering for activation (e.g., TNFR superfamily receptors). In some cases, the antibodies target two antigens on a molecule that have two or more subunits (e.g., an IL-2 receptor). Also provided herein are methods of making and using such antibodies and libraries for discovering or screening such antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to the treatment of liver cancer, e.g., hepatocellular carcinoma (HCC), e.g., resectable HCC. More specifically, the invention pertains to the treatment of patients having an HCC by administering (i) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab); (ii) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab), a VEGF antagonist (e.g., bevacizumab), and an anti-TIGIT antagonist antibody (e.g., tiragolumab); or (iii) a combination of a bispecific antibody that binds to PD-1 and LAG3 (e.g., tobemstomig) and a VEGF antagonist (e.g., bevacizumab).
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Provided herein are methods of treatment of cancers, specifically multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies in combination with anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
62.
Prevention of disulfide bond reduction during recombinant production of polypeptides
The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; diagnostic preparations for
research laboratory use; diagnostic reagents for scientific
or research use; chemical reagents for use in genetic
research; chemical preparations for use in DNA analysis
[other than medical]; biomolecule labeling kits comprising
reagents for use in scientific research; biochemicals,
namely, monoclonal antibodies for in vitro scientific or
research use; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology research;
calibration fluids for medical apparatus; reagents in kit
form for conducting enzyme-linked immunosorbent assays
(elisa) [other than for medical or veterinary purposes]. In vitro diagnostic preparations for medical use; diagnostic
reagents for medical use; reagents for use in medical
genetic testing; reagents for in-vitro laboratory use [for
medical purposes]; chemical preparations for use in DNA
analysis [medical]; preparations for detecting genetic
predispositions for medical purposes; nucleic acid sequences
for medical and veterinary purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; instruments for diagnosis [for
scientific use]; quantitative polymerase chain reaction
[PCR] instruments for scientific use; real-time polymerase
chain reaction [PCR] instruments for scientific use;
laboratory devices for detecting genetic sequences;
diagnostic apparatus for research laboratory use; DNA
microarray; devices for analyzing genome information;
devices for analyzing protein sequence used as laboratory
apparatus; research laboratory analyzers for measuring,
testing and analyzing blood and other bodily fluids; nucleic
acid sequencers for scientific purposes; laboratory devices
for detecting genetic sequences; gene amplifiers; computer
software for use in medical decision support systems;
workflow management system software; bioinformatics
software. Testing apparatus for medical purposes; diagnostic apparatus
for medical purposes; real-time polymerase chain reaction
[PCR] instruments for medical use; diagnostic testing
instruments for use in immunoassay procedure [medical];
immunochemical medical diagnostic testing apparatus for
detecting and measuring antibody levels; apparatus for DNA
and RNA testing for medical purposes; apparatus for
analysing substances [for medical use]; diagnostic apparatus
for medical purposes used in medical laboratories; genetic
testing apparatus for medical purposes. Research in the field of DNA mutation; DNA screening for
scientific research purposes; laboratory research in the
field of gene expression; consultancy relating to laboratory
testing; medical research; research and development in the
field of diagnostic preparations; providing temporary use of
on-line non-downloadable operating software for accessing
and using a cloud computing network; information on the
subject of scientific research in the field of biochemistry
and biotechnology; software as a service [SaaS].
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; diagnostic preparations for
research laboratory use; diagnostic reagents for scientific
or research use; chemical reagents for use in genetic
research; chemical preparations for use in DNA analysis
[other than medical]; biomolecule labeling kits comprising
reagents for use in scientific research; biochemicals,
namely, monoclonal antibodies for in vitro scientific or
research use; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology research;
calibration fluids for medical apparatus; reagents in kit
form for conducting enzyme-linked immunosorbent assays
(elisa) [other than for medical or veterinary purposes]. In vitro diagnostic preparations for medical use; diagnostic
reagents for medical use; reagents for use in medical
genetic testing; reagents for in-vitro laboratory use [for
medical purposes]; chemical preparations for use in DNA
analysis [medical]; preparations for detecting genetic
predispositions for medical purposes; nucleic acid sequences
for medical and veterinary purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; instruments for diagnosis [for
scientific use]; quantitative polymerase chain reaction
[PCR] instruments for scientific use; real-time polymerase
chain reaction [PCR] instruments for scientific use;
laboratory devices for detecting genetic sequences;
diagnostic apparatus for research laboratory use; DNA
microarray; devices for analyzing genome information;
devices for analyzing protein sequence used as laboratory
apparatus; research laboratory analyzers for measuring,
testing and analyzing blood and other bodily fluids; nucleic
acid sequencers for scientific purposes; laboratory devices
for detecting genetic sequences; gene amplifiers; computer
software for use in medical decision support systems;
workflow management system software; bioinformatics
software. Testing apparatus for medical purposes; diagnostic apparatus
for medical purposes; real-time polymerase chain reaction
[PCR] instruments for medical use; diagnostic testing
instruments for use in immunoassay procedure [medical];
immunochemical medical diagnostic testing apparatus for
detecting and measuring antibody levels; apparatus for DNA
and RNA testing for medical purposes; apparatus for
analysing substances [for medical use]; diagnostic apparatus
for medical purposes used in medical laboratories; genetic
testing apparatus for medical purposes. Research in the field of DNA mutation; DNA screening for
scientific research purposes; laboratory research in the
field of gene expression; consultancy relating to laboratory
testing; medical research; research and development in the
field of diagnostic preparations; providing temporary use of
on-line non-downloadable operating software for accessing
and using a cloud computing network; information on the
subject of scientific research in the field of biochemistry
and biotechnology; software as a service [SaaS].
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; diagnostic preparations for
research laboratory use; diagnostic reagents for scientific
or research use; chemical reagents for use in genetic
research; chemical preparations for use in DNA analysis
[other than medical]; biomolecule labeling kits comprising
reagents for use in scientific research; biochemicals,
namely, monoclonal antibodies for in vitro scientific or
research use; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology research;
calibration fluids for medical apparatus; reagents in kit
form for conducting enzyme-linked immunosorbent assays
(elisa) [other than for medical or veterinary purposes]. In vitro diagnostic preparations for medical use; diagnostic
reagents for medical use; reagents for use in medical
genetic testing; reagents for in-vitro laboratory use [for
medical purposes]; chemical preparations for use in DNA
analysis [medical]; preparations for detecting genetic
predispositions for medical purposes; nucleic acid sequences
for medical and veterinary purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; instruments for diagnosis [for
scientific use]; quantitative polymerase chain reaction
[PCR] instruments for scientific use; real-time polymerase
chain reaction [PCR] instruments for scientific use;
laboratory devices for detecting genetic sequences;
diagnostic apparatus for research laboratory use; DNA
microarray; devices for analyzing genome information;
devices for analyzing protein sequence used as laboratory
apparatus; research laboratory analyzers for measuring,
testing and analyzing blood and other bodily fluids; nucleic
acid sequencers for scientific purposes; laboratory devices
for detecting genetic sequences; gene amplifiers; computer
software for use in medical decision support systems;
workflow management system software; bioinformatics
software. Testing apparatus for medical purposes; diagnostic apparatus
for medical purposes; real-time polymerase chain reaction
[PCR] instruments for medical use; diagnostic testing
instruments for use in immunoassay procedure [medical];
immunochemical medical diagnostic testing apparatus for
detecting and measuring antibody levels; apparatus for DNA
and RNA testing for medical purposes; apparatus for
analysing substances [for medical use]; diagnostic apparatus
for medical purposes used in medical laboratories; genetic
testing apparatus for medical purposes. Research in the field of DNA mutation; DNA screening for
scientific research purposes; laboratory research in the
field of gene expression; consultancy relating to laboratory
testing; medical research; research and development in the
field of diagnostic preparations; providing temporary use of
on-line non-downloadable operating software for accessing
and using a cloud computing network; information on the
subject of scientific research in the field of biochemistry
and biotechnology; software as a service [SaaS].
67.
Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies
Herein is reported a bispecific antibody specifically binding to human Abeta protein and human transferrin receptor (bispecific anti-Abeta/TfR antibody) as well as the use of such bispecific antibodies as a medicament in the treatment of Alzheimer's Disease, including where the bispecific antibody is administered intravenously at a dose of 0.2 mg/kg to 7.2 mg/kg once every four weeks.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
68.
SULFONYLPIPERAZINYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS
The present invention relates to compounds of formula (I), wherein R1 to R3, A, Q1, Q2, W and X are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
The present invention relates to compounds of formula (I), wherein R1 to R3, A, Q1, Q2, W and X are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A battery clip for retaining at least one battery to a circuit carrier is disclosed along with an assembly including a circuit carrier having a plurality of flexible tabs and a battery clip configured to be secured to the circuit carrier to securely retain a battery thereto for providing power to the circuit carrier. The battery clip includes a plurality of slots configured to mate with and receive the flexible tabs of the circuit carrier such that the battery clip and the circuit carrier are secured together such that a first terminal of a retained battery physically contacts and is in electrical communication with the circuit carrier's first pad, the battery clip further comprising one or more flexible conductive fingers configured to contact a second terminal of a retained battery to establish an electrical communication between the fingers and the second terminal, and wherein the battery clip comprises an electrically conductive material and establishes electrical communication between the fingers and the circuit carrier's second pad.
Provided herein are methods for assessing splice-switching ASOs using a reporter to detect splicing of a cryptic sequence located in the reporter pre-mRNA.
A battery clip (110) for retaining at least one battery (162) to at least one battery contact pad (152) of a circuit carrier (150) is disclosed. The battery clip (110) comprises at least one housing (112). The housing (112) comprises at least one receptacle (114) for at least partially receiving the circuit carrier (150) and the battery (162). The receptacle (114) comprises at least one opening (116) through which the battery (162) and the circuit carrier (150) are at least partially insertable. The housing (112) comprises or is at least partially formed by at least one first contact spring element (166) and by at least one second contact spring element (118). The first contact spring element (166) and the second contact spring element (118) are configured for retaining the battery (162) to the battery contact pad (152) of the circuit carrier (150). The first contact spring element (166) is configured for contacting the battery (162) being arranged on a first side (168) of the circuit carrier (150) being inserted into the receptacle (114). The second contact spring element (118) is configured for contacting a second side (170) of the circuit carrier (150) being inserted into the receptacle (114), the second side (170) opposing the first side (168).
H01M 50/216 - Racks, modules or packs for multiple batteries or multiple cells characterised by their shape adapted for button or coin cells
H01M 50/244 - Secondary casings; Racks; Suspension devices; Carrying devices; Holders characterised by their mounting method
H01M 50/247 - Mountings; Secondary casings or frames; Racks, modules or packs; Suspension devices; Shock absorbers; Transport or carrying devices; Holders specially adapted for portable devices, e.g. mobile phones, computers, hand tools or pacemakers
H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
72.
DOUBLE STRANDED OLIGONUCLEOTIDE FOR MODULATING JAK1 EXPRESSION
The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.
Disclosed herein are compositions for use in preparing target nucleic acid molecules including one or more 5-formyl cytosine bases or adducts of 5-formyl cytosine. Also disclosed herein are methods of efficiently synthesizing nucleic acid molecules including one or more 5-formyl cytosine bases from target nucleic acid molecules which include one or more 5-hydroxymethyl cytosine bases. The present disclosure also provides for methods of detecting epigenetic modifications in a target nucleic acid molecule, such as those epigenetic modifications characterized by methylation of cytosine at the 5-position position (e.g., 5-methyl cytosine; 5-hydroxymethyl cytosine).
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes];
diagnostic biomarker reagents for medical purposes. Medical apparatus and instruments; testing apparatus for
medical purposes; diagnostic apparatus for medical purposes;
real-time polymerase chain reaction [PCR] instruments for
medical use; diagnostic testing instruments for use in
immunoassay procedure [medical]; immunochemical medical
diagnostic testing apparatus for detecting and measuring
antibody levels; apparatus for analysing substances [for
medical use]; diagnostic apparatus for medical purposes used
in medical laboratories.
05 - Pharmaceutical, veterinary and sanitary products
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes];
diagnostic biomarker reagents for medical purposes. Scientific apparatus and instruments; laboratory instruments
[other than for medical use]; instruments for diagnosis [for
scientific use]; quantitative polymerase chain reaction
[PCR] instruments for scientific use; real-time polymerase
chain reaction [PCR] instruments for scientific use;
diagnostic apparatus for research laboratory use; research
laboratory analyzers for measuring, testing and analyzing
blood and other bodily fluids; laboratory instrument for the
detection of pathogens and toxins in a biological sample for
research use. Medical apparatus and instruments; testing apparatus for
medical purposes; diagnostic apparatus for medical purposes;
real-time polymerase chain reaction [PCR] instruments for
medical use; diagnostic testing instruments for use in
immunoassay procedure [medical]; immunochemical medical
diagnostic testing apparatus for detecting and measuring
antibody levels; apparatus for analysing substances [for
medical use]; diagnostic apparatus for medical purposes used
in medical laboratories.
76.
CRYSTALLINE FORMS OF QUINAZOLINE DERIVATIVES, PREPARATION, COMPOSITION AND USE THEREOF
It is disclosed crystalline forms of (R)-N-(4-([1, 2, 4]triazolo [1, 5-c]pyrimidin-7-yloxy)-3-methylphenyl)-5-((3, 3-difluoro-1-methylpiperidin-4-yl)oxy)-6-methoxyquinazolin-4-amine, methods for the preparation thereof, pharmaceutical compositions comprising one or more of the crystalline forms as an active ingredient, and use of the crystalline forms in the treatment of hyperproliferative diseases.
The present invention relates to compounds of formula (Ib),
The present invention relates to compounds of formula (Ib),
The present invention relates to compounds of formula (Ib),
wherein R1 to R3, M and L are as described herein, and their pharmaceutically acceptable salt, enantiomers and diastereomers thereof, and compositions including the compounds and methods of using the compounds.
C07D 513/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or in which the condensed system contains four or more hetero rings
A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
78.
NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Provided herein are methods for generating a solid antigen/carrier protein gel for immunohistochemistry (IHC), as well as gels, kits and methods of use thereto. In particular, the methods, gels and kits provided herein include a purified antigen such as a polypeptide antigen, and a carrier protein such as an albumin protein, an egg white protein or mixture of egg white proteins, gelatin, or poly-lysine. Examples are provided in which the purified antigen is cross-linked to the carrier protein in the solid antigen/carrier protein gel.
22R) having the general formula (I), wherein R1to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
A61P 37/00 - Drugs for immunological or allergic disorders
C07C 35/18 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing six-membered rings with unsaturation at least in the ring
C07C 247/10 - Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 309/36 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
C07C 43/23 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
C07C 247/06 - Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated and containing rings
82.
METHODS OF PRODUCING TISSUE-DERIVED EPITHELIAL ORGANOIDS AND USES THEREOF
The present disclosure provides methods of preparing tissue-derived epithelial organoids. In particular, the present disclosure provides tissue-derived epithelial organoids embedded in hydrogel suspended in a medium. The present disclosure further provides methods of using such organoids.
The current invention is directed to an antibody comprising at least four binding sites specifically binding to an immunoglobulin Fc-region of the human IgG1 subclass comprising one, two, three or four amino acid changes compared to a wild-type Fc-region of the human IgG1 subclass for use as positive control and calibration standard in an immunoassay for the detection and quantification of anti-drug antibodies against said one, two, three or four amino acid changes in the Fc-region of the drug antibody.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
G01N 33/535 - Production of labelled immunochemicals with enzyme label
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
97.
COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1
The present invention relates to combinations of Regulator of telomere elongation helicase 1 (RTEL1) and Far Upstream Element-Binding Protein 1 (FUBP1) inhibitors, such as oligonucleotides (oligomers) that are complementary to RTEL1 or FUBP1, respectively, leading to modulation of the expression of RTEL1 and FUBP1 or modulation of RTEL1 and FUBP1 activity. The invention in particular relates to a combination of an inhibitor of RTEL1 and an inhibitor of FUBP1 for use in treating and/or preventing a disease, preferably a hepatitis B virus (HBV) infection, in particular a chronic HBV infection. The invention in particular relates to the use of a combination of RTEL1 and FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. Also comprised in the present invention is a pharmaceutical composition, a kit and the use thereof in the treatment and/or prevention of a HBV infection.
A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50% of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.
The invention provides methods and compositions for classifying kidney cancer (e.g., RCC, e.g., an inoperable, locally advanced, or metastatic RCC); methods and compositions for treating kidney cancer in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab) to the patient. Also provided are compositions, pharmaceutical compositions, kits, and articles of manufacture for use in classifying and treating kidney cancer in a patient.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
100.
PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATION THEREOF, AND METHODS OF MAKING AND USING SAME
A61J 3/10 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
A61K 9/00 - Medicinal preparations characterised by special physical form
